Biomerics Taps Veteran Leader Tyler Reed to Helm Micro Metals Division

SALT LAKE CITY, UT – February 23, 2026 – Biomerics, a major contract manufacturer for the interventional medical device industry, has appointed manufacturing veteran Tyler Reed as the new President of its Micro Metals Division. The move signals a strategic intensification of the company's focus on a critical and rapidly growing segment of the MedTech supply chain.

The appointment comes as Biomerics continues an aggressive growth strategy marked by key acquisitions and substantial investments aimed at bolstering its vertically integrated capabilities. Reed is tasked with leading a division central to producing the complex, miniature metal components that are foundational to the next generation of medical devices.

"Our success has always been rooted in innovation, manufacturing excellence and a relentless focus on serving our customers," stated Arun Mohan, Chief Executive Officer, in the company's announcement. "Tyler brings a proven track record of leading large-scale manufacturing enterprises, delivering double-digit profitable growth and executing global lean manufacturing transformations. He has led manufacturing site start-ups, scale-ups and operational turnarounds, all while building high-performance teams with a strong focus on culture that aligns strategy to execution."

A Strategic Play in a High-Growth Market

Reed’s appointment is not merely a leadership shuffle; it is a calculated move to capitalize on powerful trends within the global healthcare market. The interventional medical device sector, which Biomerics serves, is experiencing robust expansion. Valued at over $14 billion in 2024, the market is projected to surge to nearly $27 billion by 2033, driven by a global shift toward minimally invasive surgical procedures.

These advanced procedures, from cardiovascular interventions to robotic surgery, depend on sophisticated devices that are becoming increasingly smaller, more complex, and more precise. This is where the Micro Metals Division plays a pivotal role. The division specializes in micromachining, laser processing, and complex assembly of medical-grade metals like titanium, cobalt, and nitinol. These processes are essential for creating the microscopic jaws, lumens, and structural components used in steerable catheters, endoscopic tools, and robotic surgical instruments.

The demand for such precision is fueling its own sub-market. The micromachining market, a core competency for Biomerics, is projected to exceed $5 billion by 2030. Reed’s leadership is expected to sharpen Biomerics' competitive edge in capturing a larger share of this lucrative and technologically demanding field. His responsibilities will span commercial strategy, engineering, and operational excellence, directly impacting the division's ability to innovate and deliver for its top-tier clientele, which includes 20 of the world's top 30 medical device OEMs.

Fortifying a Vertically Integrated Powerhouse

The decision to bring in a leader of Reed's caliber is the logical culmination of Biomerics' recent strategic initiatives. Over the past several years, the company has methodically built one of the industry's most comprehensive micro-metals platforms through both organic growth and acquisition.

A landmark move was the May 2023 merger with Precision Concepts Medical, which significantly expanded Biomerics’ footprint in micro-metals machining, stamping, and micro-assembly. This followed the 2021 acquisition of Berg Manufacturing Inc., a leader in Swiss micromachining for robotic surgery, and Knight Machining LLC, a metal component and laser processing specialist. These acquisitions were not just about adding capacity; they were about integrating critical, high-precision technologies under one roof.

Alongside acquisitions, the company has invested heavily in its infrastructure. It recently completed a 100,000-square-foot expansion of its Brooklyn Park, Minnesota facility, which houses advanced micro metals laser processing. It has also doubled its manufacturing footprint in Costa Rica, a key medical device manufacturing hub. Most recently, in October 2024, Biomerics launched a new Metal Injection Molding (MIM) Center of Excellence, a technology that enables high-volume production of highly complex metal parts for surgical robotics and other advanced devices. With these assets now in place, Reed’s primary role will be to optimize, integrate, and scale these operations to their full potential.

The Reed Playbook: Excellence in Operations and Culture

Tyler Reed's background appears tailor-made for the challenge. His experience is not just in managing manufacturing but in transforming it. As noted by CEO Arun Mohan, Reed has led "manufacturing site start-ups, scale-ups and operational turnarounds." This expertise in implementing lean manufacturing principles will be crucial for integrating disparate facilities and processes into a seamless, efficient engine.

In his own statement, Reed outlined his priorities. "I will primarily focus on driving improvements in efficiency, resource utilization, employee engagement and retention, and production," he said, aligning his goals with the company's "strategic pillars of customer excellence, culture, innovation and manufacturing excellence."

His emphasis on "employee engagement and retention" is particularly noteworthy. In the highly specialized field of medical device manufacturing, skilled engineers, machinists, and technicians are a critical asset. Retaining this talent is paramount to maintaining quality and fostering innovation. Reed's stated commitment to building "high-performance teams with a strong focus on culture" suggests a leadership style that recognizes the human element as a key driver of manufacturing success. This approach is vital for creating a stable, motivated workforce capable of handling the intricate and exacting demands of producing life-saving medical components.

As Biomerics consolidates its position as a dominant force in interventional device contract manufacturing, Reed’s leadership will be instrumental. His task is to harness the company's significant investments in technology and infrastructure and translate them into market-leading performance, ensuring the Micro Metals Division can meet the ever-increasing complexity and quality demands of the MedTech industry. This focus on operational discipline and cultural strength is poised to drive the next chapter of growth for Biomerics' most intricate manufacturing segment.